It’s known that thiazolidinediones reduce bone density; insulin increases the risk of fractures (probably as a result of an increase in falls, related to episodes of hypoglycemia and the fact that insulin is used in the most serious cases); metformin has neutral effects on bone, instead studies are not unique for sodium/glucose cotransporter 2 (SGLT-2) (in particular canagliflozin) [2–4]. The gene discussed is SLC5A2; the disease is Hypoglycemia.